X0508 4 2026-02-02 0001842295 Maze Therapeutics, Inc. MAZE 0002050422 Bachrodt Amy C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 false true false false SVP, Finance 1 Common Stock 2026-02-02 4 M 0 4844 10.42 A 17809 D Common Stock 2026-02-02 4 M 0 156 10.42 A 17965 D Common Stock 2026-02-02 4 S 0 200 44.1500 D 17765 D Common Stock 2026-02-02 4 S 0 4064 46.0305 D 13701 D Common Stock 2026-02-02 4 S 0 736 46.6323 D 12965 D Stock Option (Right to Buy) 10.42 2026-02-02 4 M 0 4844 0 D 2032-02-17 Common Stock 4844 3025 D Stock Option (Right to Buy) 10.42 2026-02-02 4 M 0 156 0 D 2034-12-08 Common Stock 156 41333 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.345 to $46.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.365 to $47.23 per share, inclusive. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. /s/ Courtney Phillips, as attorney-in-fact 2026-02-04